epidem
sever
atyp
pneumonia
design
sever
acut
respiratori
syndrom
sar
world
health
organ
first
observ
guangdong
provinc
china
novemb
affect
peopl
caus
death
countri
area
worldwid
august
novel
coronaviru
sarsassoci
coronaviru
sarscov
confirm
pathogen
absenc
effect
drug
control
diseas
reli
rapid
identif
case
appropri
manag
close
contact
effect
vaccin
sar
therefor
develop
specif
sensit
laboratori
test
sar
well
effect
vaccin
necessari
nation
author
laboratori
test
sar
base
indirect
immunofluoresc
assay
ifa
viral
particl
lysat
enzymelink
immunosorb
assay
sarscov
lysat
elisa
detect
antibodi
sarscov
import
method
howev
method
requir
cultiv
sarscov
biosafeti
level
laboratori
danger
difficult
find
suitabl
diagnost
test
viru
therefor
remain
high
prioriti
practic
approach
toward
goal
clone
express
immunodomin
gene
sarscov
sever
studi
shown
antigen
epitop
sarscov
locat
nucleocapsid
n
spike
protein
latter
protein
import
role
viral
entri
pathogenesi
data
shown
viral
n
protein
coronavirus
could
induc
specif
cell
respons
report
clone
express
truncat
sn
fusion
protein
sarscov
investig
antigen
immunogen
vector
purchas
qiagen
qiagen
gmbh
hilden
germani
escherichia
coli
use
host
strain
vector
follow
viru
strain
kindli
provid
academi
militari
medic
scienc
nation
institut
control
pharmaceut
biolog
product
sarscov
sarscov
human
coronaviru
human
coronaviru
work
infecti
viru
perform
biosafeti
level
laboratori
viral
rna
extract
trizol
accord
manual
invitrogen
primer
synthes
shanghai
sangon
compani
accord
publish
dna
sequenc
tabl
genom
sarscov
sequenc
n
protein
well
truncat
n
protein
amplifi
rtpcr
mixtur
deoxynucleosid
triphosph
primer
u
taq
polymeras
takara
mm
trishcl
buffer
ph
supplement
mm
mm
kcl
pcr
reaction
start
min
follow
cycl
cycl
consist
sec
sec
sec
final
step
min
ad
last
cycl
fusion
gene
construct
establish
express
truncat
sn
fusion
protein
recombin
plasmid
construct
describ
elsewher
restrict
enzym
ligas
purchas
takara
biotechnolog
co
ltd
dalian
china
e
coli
transform
ligat
mixtur
control
vector
respect
presenc
target
gene
recombin
plasmid
verifi
genespecif
pcr
sequenc
analysi
sar
patient
sera
serum
sampl
sar
convalesc
day
onset
ill
fulfil
clinic
case
definit
sar
whose
diagnosi
subsequ
confirm
seroconvers
collect
hospit
beij
china
hospit
beij
china
sera
test
posit
sarscov
lysat
elisa
igg
kit
beij
bgigbi
biotech
corp
approv
state
food
drug
administr
sfda
detect
antisarscov
immunoglobulin
ig
g
antibodi
human
serum
plasma
specimen
sera
healthi
blood
donor
collect
beij
red
cross
blood
center
may
octob
polyclon
mous
sera
sarscov
hcov
hcov
prepar
laboratori
ifa
dilut
respect
polyclon
mous
sera
purifi
recombin
protein
sarscov
n
hcov
n
hcov
n
ifa
dilut
respect
control
sera
collect
healthi
balbc
mice
mous
immun
perform
accord
establish
protocol
briefli
sixteen
balbc
mice
divid
group
inject
subcutan
ml
purifi
recombin
fusion
truncat
sn
protein
solut
pb
respect
mix
equal
volum
paraffin
oil
immun
mice
boost
day
use
half
dose
antigen
celiac
arteri
rout
immunoblot
analysi
perform
describ
detail
elsewher
sdspage
analysi
perform
use
miniprotein
electrophoresi
system
biorad
stack
gel
separ
gel
contain
acrylamid
respect
electrophoresi
carri
constant
voltag
v
min
protein
electroblot
onto
nitrocellulos
membran
mous
sera
test
recombin
protein
indirect
immunofluoresc
assay
ifa
perform
detect
antibodi
sarscov
hcov
hcov
use
sarscov
accord
establish
protocol
microtit
plate
well
shenzhen
jinchanhua
co
ltd
coat
overnight
either
eight
recombin
antigen
four
recombin
antigen
sarscov
truncat
protein
n
protein
truncat
n
protein
truncat
sn
fusion
protein
two
recombin
antigen
truncat
n
protein
n
protein
two
recombin
antigen
truncat
n
protein
n
protein
dilut
mm
buffer
ph
well
rins
pb
phosphatebuff
salin
contain
bsa
block
remain
proteinbind
site
incub
hour
plate
wash
five
time
buffer
dilut
serum
sampl
pb
ad
plate
plate
incub
min
wash
five
time
buffer
addit
peroxidaseconjug
goat
antihuman
igg
dilut
pb
supplement
bsa
well
plate
incub
min
wash
five
time
buffer
addit
tetramethylbenzidin
tmb
hydrogen
peroxid
substrat
reaction
stop
addit
valu
measur
microtit
plate
reader
triplic
blank
control
neg
control
posit
control
alway
includ
plate
cutoff
valu
igg
three
n
protein
truncat
protein
three
truncat
n
protein
truncat
sn
protein
respect
calcul
mean
sd
read
given
blood
donor
control
sera
collect
beij
sampl
test
triplic
valu
near
cutoff
valu
detect
mice
antibodi
procedur
detect
human
antibodi
except
peroxidaseconjug
goat
antimic
igg
dilut
use
mice
sera
dilut
pb
neutral
titer
nt
mous
sera
measur
rapid
microneutr
assay
brief
heatinactiv
min
mous
immun
serum
dilut
tenfold
serial
dilut
twofold
dmem
gibco
contain
heatinactiv
fetal
calf
serum
min
approxim
sarscov
strain
mix
equal
volum
dilut
serum
incub
h
ul
mixtur
contain
dmem
contain
inactiv
fetal
calf
serum
ad
onto
cell
monolay
triplic
viral
cytopath
effect
cpe
observ
day
dilut
serum
complet
prevent
cpe
well
calcul
accord
reed
muench
formula
serolog
crossreact
among
differ
human
coronavirus
test
incub
sarscovinfect
cell
mous
antisera
two
human
coronavirus
subsequ
indirect
immunofluoresc
assay
ifa
evalu
crossreact
among
differ
recombin
protein
three
human
coronavirus
protein
subject
immunoblot
assay
mous
antisera
protein
well
antisera
virus
also
subject
elisa
serum
sampl
sar
convalesc
well
mice
antisera
virus
serum
sampl
collect
tail
vein
everi
day
initi
immun
final
serum
sampl
collect
orbit
plexu
antibodi
level
assess
sarscov
lysat
elisa
igg
kit
accord
manufactur
instruct
except
peroxidaseconjug
goat
antihuman
igg
substitut
peroxidaseconjug
goat
antimous
igg
sihuan
scitechn
compani
beij
valu
sn
taken
posit
standard
prolifer
spleen
lymphocyt
measur
colorimetr
analysi
describ
previous
four
balbc
mice
group
kill
day
immun
spleen
ground
singlecel
suspens
rpmi
medium
gibco
supplement
fetal
calf
serum
suspens
mix
volum
erythrocyt
lysi
buffer
trishcl
ph
nacl
incub
minut
ice
centrifug
g
min
pellet
resuspend
rpmi
medium
gibco
supplement
fetal
calf
serum
seed
triplic
flatbottom
microtit
plate
costar
cell
per
well
cultur
medium
purifi
truncat
sn
protein
respect
incub
day
solut
tetrazolium
salt
bromid
mtt
ad
well
plate
incub
h
one
hundr
microlit
lysi
buffer
contain
hydrochlor
acid
ad
well
plate
incub
overnight
optic
densiti
nm
nm
measur
four
balbc
mice
group
immun
well
control
challeng
intranas
sarscov
strain
day
immun
test
heterolog
protect
two
day
clinic
observ
mice
sacrif
lung
collect
determin
level
viral
rna
fifti
mg
lung
tissu
first
homogen
liquid
nitrogen
ml
trizol
tissu
homogen
clarifi
lowspe
centrifug
rpm
rna
extract
perform
accord
manual
invitrogen
viru
load
determin
fluoresc
quantit
rtpcr
express
number
copi
per
gram
tissu
result
immunofluoresc
analysi
crossreact
sarscovinfect
cell
mous
antisera
n
protein
three
coronavirus
shown
figur
result
show
mous
antisera
n
protein
n
protein
crossreact
sarscov
figur
show
result
immunoblot
analys
crossreact
intact
n
protein
three
human
coronavirus
plu
truncat
protein
mous
antisera
coronaviru
panel
b
c
ii
truncat
n
protein
coronaviru
mous
antisera
coronaviru
panel
e
f
result
show
crossreact
intact
n
protein
antisera
three
coronavirus
b
crossreact
antisera
truncat
protein
recombin
protein
also
test
serum
sampl
sar
convalesc
elisa
result
show
sera
test
posit
n
protein
respect
none
sera
test
posit
truncat
n
protein
qualiti
truncat
protein
n
protein
truncat
n
protein
truncat
sn
fusion
protein
diagnost
antigen
evalu
elisa
techniqu
describ
materi
method
sar
patient
sera
test
four
antigen
sampl
test
neg
truncat
sn
fusion
protein
assay
wherea
sampl
test
neg
truncat
protein
n
protein
truncat
n
protein
assay
respect
tabl
compar
sarscov
lysat
elisa
sensit
elisa
truncat
protein
n
protein
truncat
n
protein
truncat
sn
fusion
protein
antigen
respect
evalu
specif
assay
sera
healthi
peopl
test
gave
posit
reaction
either
sarscov
lysat
n
protein
wherea
none
react
truncat
protein
tabl
evalu
specif
truncat
sn
fusion
protein
polyclon
mous
sera
sarscov
antisera
test
elisa
mice
antiserum
sarscov
test
posit
sera
antibodi
test
show
abil
fusion
protein
induc
gener
sarsspecif
antibodi
immun
mice
nine
twelv
day
inject
specif
ig
g
antibodi
could
detect
test
whether
mous
sera
truncat
sn
protein
abl
neutral
sarscov
properti
like
crucial
defens
viru
infect
sarscov
strain
use
microneutr
assay
describ
materi
method
serum
titer
neutral
antibodi
sarscov
lg
dilut
sd
lymphocyt
prolifer
assay
show
truncat
sn
protein
could
induc
cell
prolifer
mice
immun
truncat
fusion
protein
tabl
signific
differ
mice
immun
truncat
fusion
protein
control
test
p
clinic
sign
ill
observ
either
group
sarschalleng
mice
analysi
sarscov
genom
copi
lung
immun
mice
control
perform
mean
viru
genom
copi
number
copiesg
sd
per
gram
lung
tissu
control
group
wherea
viru
load
mice
immun
truncat
sn
protein
limit
detect
sar
newli
emerg
infecti
diseas
caus
worldwid
outbreak
crucial
public
health
problem
establish
specif
conveni
laboratori
test
sar
find
vaccin
viru
high
prioriti
previou
data
shown
high
degre
sequenc
similar
nucleocapsid
n
protein
coronavirus
demonstr
seriou
serolog
crossreact
align
n
protein
five
human
coronavirus
sarscov
found
sever
fairli
homolog
region
eg
sarscov
region
n
protein
sarscov
ident
amino
acid
sequenc
n
protein
hcov
hcov
ident
amino
acid
sequenc
figur
also
found
ctermin
n
protein
sarscov
lower
ident
amino
acid
sequenc
among
human
coronavirus
figur
addit
previou
research
show
uniqu
highli
antigen
site
locat
ctermin
part
sar
n
protein
sar
spike
protein
research
also
show
ctermin
part
sar
n
protein
highli
antigen
present
studi
use
express
vector
clone
n
gene
gene
segment
encod
ctermin
part
n
protein
three
coronavirus
well
sarscov
gene
segment
encod
truncat
spike
protein
aa
truncat
sn
fusion
protein
respect
protein
highli
express
e
coli
evalu
crossreact
recombin
protein
virus
ifa
immunoblot
assay
perform
result
figur
show
truncat
protein
react
speciesspecif
antiserum
n
protein
crossreact
virus
elisa
result
also
show
intact
n
protein
crossreact
sar
patient
sera
respect
truncat
n
protein
crossreact
sar
patient
sera
use
purifi
protein
antigen
elisa
assay
antibodi
sera
sar
patient
found
assay
use
truncat
sn
fusion
protein
clearli
higher
sensit
use
intact
n
protein
truncat
n
protein
virtual
high
assay
use
whole
sarscov
lysat
tabl
result
indic
n
protein
complementari
detect
sarsspecif
antibodi
consist
previou
studi
five
posit
sera
sarscov
lysat
antigen
test
posit
sarscov
n
protein
neg
sarscov
truncat
ns
protein
sera
also
test
posit
n
protein
data
shown
could
reason
explain
partli
exist
hcov
infect
human
truncat
sn
fusion
protein
also
subject
elisa
mice
antisera
sarscov
mice
antiserum
sarscov
test
posit
result
show
sarscov
truncat
ns
protein
high
specif
consid
difficulti
sarscov
lysat
antigen
product
fals
posit
ratio
tabl
truncat
sn
fusion
protein
suitabl
diagnost
antigen
detect
sarscov
antibodi
protein
sarscov
import
determin
tissu
tropism
mediat
viru
cellular
membran
fusion
analysi
neutral
epitop
show
receptorbind
region
protein
play
import
role
viru
infect
dna
vaccin
studi
sarscov
also
shown
protein
induc
protect
immun
respons
sarscov
moreov
data
show
n
protein
sarscov
could
induc
specif
tcell
respons
studi
anim
coronavirus
suggest
cellular
humor
immun
contribut
protect
persist
infect
consid
fusion
protein
includ
receptorbind
region
protein
immunodomin
tcell
epitop
n
protein
also
investig
role
truncat
sn
protein
antisarscov
infect
seven
nine
day
inject
fusion
protein
mice
began
show
seroposit
sar
antibodi
first
booster
mice
gener
high
titer
sarsspecif
antibodi
antibodi
could
neutral
sarscov
infect
lymphocyt
prolifer
assay
truncat
sn
protein
could
induc
cell
prolifer
tabl
compar
control
group
mice
immun
truncat
sn
protein
protect
sarscov
challeng
indic
lack
detect
viral
rna
therefor
addit
valuabl
diagnost
antigen
truncat
sn
fusion
protein
potenti
candid
develop
sar
subunit
vaccin
truncat
sn
fusion
protein
high
sensit
specif
suitabl
diagnost
antigen
detect
sarscov
antibodi
hand
could
induc
mice
gener
high
titer
sarsspecif
neutral
antibodi
cell
prolifer
mice
immun
truncat
sn
protein
protect
sarscov
challeng
also
potenti
candid
develop
sar
subunit
vaccin
author
declar
compet
interest
fm
carri
gene
clone
protein
express
draft
manuscript
dsn
carri
virus
challeng
assay
partial
immunoassay
jsm
carri
clinic
sampl
collect
partial
immunoassay
bh
wgh
syh
particip
sampl
detect
bxf
yq
particip
sampl
collect
wjc
design
studi
perform
data
analysi
wrote
manuscript
author
read
approv
final
manuscript
